GAMMA Investing LLC Buys 214 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

GAMMA Investing LLC lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 58.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 583 shares of the biotechnology company’s stock after purchasing an additional 214 shares during the period. GAMMA Investing LLC’s holdings in Ascendis Pharma A/S were worth $80,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth about $30,000. Groupama Asset Managment bought a new stake in Ascendis Pharma A/S during the third quarter worth about $60,000. Signaturefd LLC grew its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 80 shares during the period. Rhumbline Advisers increased its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares in the last quarter. Finally, Pursue Wealth Partners LLC purchased a new position in shares of Ascendis Pharma A/S during the third quarter valued at approximately $217,000.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wedbush restated an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Citigroup increased their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 17th. Oppenheimer dropped their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Stock Down 3.9 %

ASND opened at $129.19 on Friday. The stock has a market capitalization of $7.84 billion, a price-to-earnings ratio of -15.99 and a beta of 0.65. The firm has a 50 day moving average price of $132.61 and a 200-day moving average price of $133.58. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.